Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2011

Open Access 01-12-2011 | Research

Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells

Authors: Minfeng Shu, Xiaoke Zheng, Sihan Wu, Huimin Lu, Tiandong Leng, Wenbo Zhu, Yuehan Zhou, Yanqiu Ou, Xi Lin, Yuan Lin, Dong Xu, Yuxi Zhou, Guangmei Yan

Published in: Molecular Cancer | Issue 1/2011

Login to get access

Abstract

Background

Astrocytomas are the most common and aggressive brain tumors characterized by their highly invasive growth. Gain of chromosome 7 with a hot spot at 7q32 appears to be the most prominent aberration in astrocytoma. Previously reports have shown that microRNA-335 (miR-335) resided on chromosome 7q32 is deregulated in many cancers; however, the biological function of miR-335 in astrocytoma has yet to be elucidated.

Results

We report that miR-335 acts as a tumor promoter in conferring tumorigenic features such as growth and invasion on malignant astrocytoma. The miR-335 level is highly elevated in C6 astrocytoma cells and human malignant astrocytomas. Ectopic expression of miR-335 in C6 cells dramatically enhances cell viability, colony-forming ability and invasiveness. Conversely, delivery of antagonist specific for miR-335 (antagomir-335) to C6 cells results in growth arrest, cell apoptosis, invasion repression and marked regression of astrocytoma xenografts. Further investigation reveals that miR-335 targets disheveled-associated activator of morphogenesis 1(Daam1) at posttranscriptional level. Moreover, silencing of endogenous Daam1 (siDaam1) could mimic the oncogenic effects of miR-335 and reverse the growth arrest, proapoptotic and invasion repression effects induced by antagomir-335. Notably, the oncogenic effects of miR-335 and siDAAM1 together with anti-tumor effects of antagomir-335 are also confirmed in human astrocytoma U87-MG cells.

Conclusion

These findings suggest an oncogenic role of miR-335 and shed new lights on the therapy of malignant astrocytomas by targeting miR-335.
Appendix
Available only for authorised users
Literature
1.
2.
Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, Krichevsky AM: MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol. 2008, 28: 5369-5380. 10.1128/MCB.00479-08PubMedCentralCrossRefPubMed
3.
Esquela-Kerscher A, Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006, 6: 259-269. 10.1038/nrc1840CrossRefPubMed
4.
Medina PP, Slack FJ: microRNAs and cancer: an overview. Cell Cycle. 2008, 7: 2485-2492. 10.4161/cc.7.16.6453CrossRefPubMed
5.
6.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA: MicroRNA expression profiles classify human cancers. Nature. 2005, 435: 834-838. 10.1038/nature03702CrossRefPubMed
7.
Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger K: Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 2009, 69: 4851-4860. 10.1158/0008-5472.CAN-08-4043CrossRefPubMed
8.
Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, Beer DG: MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009, 69: 5776-5783. 10.1158/0008-5472.CAN-09-0587CrossRefPubMed
9.
Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. Jama. 2008, 299: 425-436. 10.1001/jama.299.4.425PubMedCentralPubMed
10.
Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, Slack FJ: Regression of murine lung tumors by the let-7 microRNA. Oncogene. 2009
11.
Trang P, Weidhaas JB, Slack FJ: MicroRNAs as potential cancer therapeutics. Oncogene. 2008, 27 (Suppl 2): S52-57. 10.1038/onc.2009.353CrossRefPubMed
12.
Holland H, Koschny T, Ahnert P, Meixensberger J, Koschny R: WHO grade-specific comparative genomic hybridization pattern of astrocytoma-A meta-analysis. Pathol Res Pract. 2010
13.
Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D: Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA. 2009, 106: 1814-1819. 10.1073/pnas.0808263106PubMedCentralCrossRefPubMed
14.
Lowery AJ, Miller N, Dwyer RM, Kerin MJ: Dysregulated miR-183 inhibits migration in breast cancer cells. BMC Cancer. 2010, 10: 502- 10.1186/1471-2407-10-502PubMedCentralCrossRefPubMed
15.
Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W, Liu J, Yu J, Chen J: miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res. 2010, 70: 6015-6025. 10.1158/0008-5472.CAN-09-4531CrossRefPubMed
16.
Png KJ, Yoshida M, Zhang XH, Shu W, Lee H, Rimner A, Chan TA, Comen E, Andrade VP, Kim SW: MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev. 2011, 25: 226-231. 10.1101/gad.1974211PubMedCentralCrossRefPubMed
17.
Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague J: Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008, 451: 147-152. 10.1038/nature06487PubMedCentralCrossRefPubMed
18.
Scarola M, Schoeftner S, Schneider C, Benetti R: miR-335 directly targets Rb1 (pRb/p105) in a proximal connection to p53-dependent stress response. Cancer Res. 2010, 70: 6925-6933. 10.1158/0008-5472.CAN-10-0141CrossRefPubMed
19.
Tome M, Lopez-Romero P, Albo C, Sepulveda JC, Fernandez-Gutierrez B, Dopazo A, Bernad A, Gonzalez MA: miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells. Cell Death Differ.
20.
Shu M, Zhou Y, Zhu W, Wu S, Zheng X, Yan G: Activation of a pro-survival pathway IL-6/JAK2/STAT3 contributes to glial fibrillary acidic protein induction during the cholera toxin-induced differentiation of C6 malignant glioma cells. Mol Oncol. 2011
21.
Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, Zhuang SM: MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009, 69: 1135-1142. 10.1158/0008-5472.CAN-08-2886CrossRefPubMed
22.
Akagi T, Murata K, Shishido T, Hanafusa H: v-Crk activates the phosphoinositide 3-kinase/AKT pathway by utilizing focal adhesion kinase and H-Ras. Mol Cell Biol. 2002, 22: 7015-7023. 10.1128/MCB.22.20.7015-7023.2002PubMedCentralCrossRefPubMed
23.
Deng J, Miller SA, Wang HY, Xia W, Wen Y, Zhou BP, Li Y, Lin SY, Hung MC: beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell. 2002, 2: 323-334. 10.1016/S1535-6108(02)00154-XCrossRefPubMed
24.
Soltani MH, Pichardo R, Song Z, Sangha N, Camacho F, Satyamoorthy K, Sangueza OP, Setaluri V: Microtubule-associated protein 2, a marker of neuronal differentiation, induces mitotic defects, inhibits growth of melanoma cells, and predicts metastatic potential of cutaneous melanoma. Am J Pathol. 2005, 166: 1841-1850. 10.1016/S0002-9440(10)62493-5PubMedCentralCrossRefPubMed
25.
Astolfi A, Nannini M, Pantaleo MA, Di Battista M, Heinrich MC, Santini D, Catena F, Corless CL, Maleddu A, Saponara M: A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. Lab Invest. 2010
26.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352: 987-996. 10.1056/NEJMoa043330CrossRefPubMed
27.
Lefranc F, Brotchi J, Kiss R: Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol. 2005, 23: 2411-2422. 10.1200/JCO.2005.03.089CrossRefPubMed
28.
Calin GA, Croce CM: MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene. 2006, 25: 6202-6210. 10.1038/sj.onc.1209910CrossRefPubMed
29.
Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008, 27: 2128-2136. 10.1038/sj.onc.1210856CrossRefPubMed
30.
Silber J, James CD, Hodgson JG: microRNAs in gliomas: small regulators of a big problem. Neuromolecular Med. 2009, 11: 208-222. 10.1007/s12017-009-8087-9CrossRefPubMed
31.
Marsh EE, Lin Z, Yin P, Milad M, Chakravarti D, Bulun SE: Differential expression of microRNA species in human uterine leiomyoma versus normal myometrium. Fertil Steril. 2008, 89: 1771-1776. 10.1016/j.fertnstert.2007.05.074PubMedCentralCrossRefPubMed
32.
Ronchetti D, Lionetti M, Mosca L, Agnelli L, Andronache A, Fabris S, Deliliers GL, Neri A: An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Med Genomics. 2008, 1: 37- 10.1186/1755-8794-1-37PubMedCentralCrossRefPubMed
33.
Uziel T, Karginov FV, Xie S, Parker JS, Wang YD, Gajjar A, He L, Ellison D, Gilbertson RJ, Hannon G, Roussel MF: The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci USA. 2009, 106: 2812-2817. 10.1073/pnas.0809579106PubMedCentralCrossRefPubMed
34.
Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ: Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis. 2010, 11: 50-54. 10.1111/j.1751-2980.2009.00413.xCrossRefPubMed
35.
Asai A, Miyagi Y, Sugiyama A, Gamanuma M, Hong SH, Takamoto S, Nomura K, Matsutani M, Takakura K, Kuchino Y: Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy. J Neurooncol. 1994, 19: 259-268. 10.1007/BF01053280CrossRefPubMed
36.
Zupanska A, Dziembowska M, Ellert-Miklaszewska A, Gaweda-Walerych K, Kaminska B: Cyclosporine a induces growth arrest or programmed cell death of human glioma cells. Neurochem Int. 2005, 47: 430-441. 10.1016/j.neuint.2005.05.010CrossRefPubMed
37.
Vasudevan S, Tong Y, Steitz JA: Switching from repression to activation: microRNAs can up-regulate translation. Science. 2007, 318: 1931-1934. 10.1126/science.1149460CrossRefPubMed
38.
Bhattacharyya SN, Habermacher R, Martine U, Closs EI, Filipowicz W: Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell. 2006, 125: 1111-1124. 10.1016/j.cell.2006.04.031CrossRefPubMed
39.
Kedde M, Strasser MJ, Boldajipour B, Oude Vrielink JA, Slanchev K, le Sage C, Nagel R, Voorhoeve PM, van Duijse J, Orom UA: RNA-binding protein Dnd1 inhibits microRNA access to target mRNA. Cell. 2007, 131: 1273-1286. 10.1016/j.cell.2007.11.034CrossRefPubMed
40.
Li D, Hallett MA, Zhu W, Rubart M, Liu Y, Yang Z, Chen H, Haneline LS, Chan RJ, Schwartz RJ: Dishevelled-associated activator of morphogenesis 1 (Daam1) is required for heart morphogenesis. Development. 2011, 138: 303-315. 10.1242/dev.055566PubMedCentralCrossRefPubMed
41.
Ang SF, Zhao ZS, Lim L, Manser E: DAAM1 is a formin required for centrosome re-orientation during cell migration. PLoS One. 2010, 5:
42.
LaMonica K, Bass M, Grabel L: The planar cell polarity pathway directs parietal endoderm migration. Dev Biol. 2009, 330: 44-53. 10.1016/j.ydbio.2009.03.008PubMedCentralCrossRefPubMed
43.
Ju R, Cirone P, Lin S, Griesbach H, Slusarski DC, Crews CM: Activation of the planar cell polarity formin DAAM1 leads to inhibition of endothelial cell proliferation, migration, and angiogenesis. Proc Natl Acad Sci USA. 2010
44.
Salhia B, Rutten F, Nakada M, Beaudry C, Berens M, Kwan A, Rutka JT: Inhibition of Rho-kinase affects astrocytoma morphology, motility, and invasion through activation of Rac1. Cancer Res. 2005, 65: 8792-8800. 10.1158/0008-5472.CAN-05-0160CrossRefPubMed
45.
Shi J, Wei L: Rho kinase in the regulation of cell death and survival. Arch Immunol Ther Exp (Warsz). 2007, 55: 61-75. 10.1007/s00005-007-0009-7.CrossRef
46.
Song Y, Hoang BQ, Chang DD: ROCK-II-induced membrane blebbing and chromatin condensation require actin cytoskeleton. Exp Cell Res. 2002, 278: 45-52. 10.1006/excr.2002.5565CrossRefPubMed
47.
Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND: MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007, 13: 613-618. 10.1038/nm1582CrossRefPubMed
48.
Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S: MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008, 456: 980-984. 10.1038/nature07511CrossRefPubMed
49.
Felicetti F, Errico MC, Bottero L, Segnalini P, Stoppacciaro A, Biffoni M, Felli N, Mattia G, Petrini M, Colombo MP: The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res. 2008, 68: 2745-2754. 10.1158/0008-5472.CAN-07-2538CrossRefPubMed
50.
Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M, Boldrini R, Donfrancesco A, Federici V, Giacomini P: Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One. 2008, 3: e2236- 10.1371/journal.pone.0002236PubMedCentralCrossRefPubMed
Metadata
Title
Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells
Authors
Minfeng Shu
Xiaoke Zheng
Sihan Wu
Huimin Lu
Tiandong Leng
Wenbo Zhu
Yuehan Zhou
Yanqiu Ou
Xi Lin
Yuan Lin
Dong Xu
Yuxi Zhou
Guangmei Yan
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2011
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-10-59

Other articles of this Issue 1/2011

Molecular Cancer 1/2011 Go to the issue

Research

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines

Research

Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming

Research

Kinome expression profiling and prognosis of basal breast cancers

Research

Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells

Research

Aurora-A inactivation causes mitotic spindle pole fragmentation by unbalancing microtubule-generated forces

Research

Sodium ion channel mutations in glioblastoma patients correlate with shorter survival
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits